医学临床研究
  2025年4月5日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2018, Vol. 35 Issue (12): 2332-2334    DOI: 10.3969/j.issn.1671-7171.2018.12.014
  论著 本期目录 | 过刊浏览 | 高级检索 |
左舒必利、多潘立酮和胃复安治疗功能性消化不良的安全性及疗效比较
魏铁军1a, 张恒1b, 郭艺静1c, 张永利2, 姜萌2, 白云磊3
1.北京中医药大学孙思邈医院: a.消化内科;b.检验科;c.内分泌科,陕西 铜川 727000;
2.铜川市人民医院南院消化科,陕西 铜川 727000;
3.榆林市第一医院消化内科,陕西 榆林 719000
Safety and Efficacy of Levosulpiride, Domperidone and Metoclopramide in the Treatment of Functional Dyspepsia
WEI Tie-jun, ZHANG Heng, GUO Yi-jing, et al
Department of Digestive Medicine, the SunSimiao Hospital, Beijing University of Traditional Chinese Medicine,Tongchuan 727000
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】 评估并比较左舒必利、多潘立酮和胃复安三种不同药物治疗功能性消化不良的安全性及临床疗效。【方法】 选取2014年6月至2015年3月于本院确诊为功能性消化不良患者150例,随机分为三组,每组各50例。三组患者分别接受左舒必利、多潘立酮和胃复安药物治疗。利用利兹消化不良问卷及李克特五点量表法评估患者治疗前后的功能性消化不良症状程度。【结果】 150例患者中,有143例患者(左舒必利组50例、多潘立酮组45例和胃复安组48例)成功完成本试验。三种药物都能不同程度改善患者的功能性消化不良症状,但左舒必利组患者消化不良症状的总体改善程度显著高于其他两组(P<0.05),且患者不良反应(包括恶心、头痛、腹泻等)的发生率最低。【结论】 左舒必利相对于多潘立酮和胃复安在治疗功能性消化不良方面具有更高的安全性及疗效。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 消化不良/药物疗法药用制剂    
Abstract【Objective】 To evaluate and compare the safety and clinical efficacy of levosulpiride, domperidone and metoclopramide in the treatment of functional dyspepsia.【Methods】 One hundred and fifty patients with functional dyspepsia from June 2014 to March 2015 were randomly divided into three groups with 50 cases in each group. The three groups were treated with levosulpiride, domperidone and metoclopramide respectively. The degree of functional dyspepsia before and after treatment was evaluated by Leeds indigestion questionnaire and Likert five-point scale. 【Results】 143 of 150 patients (50 in the levosulpiride group, 45 in the domperidone group and 48 in the metoclopramide group) completed the test successfully. All three drugs can improve patients' symptoms of functional dyspepsia to varying degrees. However, the overall improvement of dyspepsia in the levosulpiride group was significantly higher than that in the other two groups (P<0.05), and the incidence of adverse reactions (including nausea, headache, diarrhea, etc.) was the lowest in the levosulpiride group.【Conclusion】 Levosulpiride has higher safety and efficacy than domperidone and metoclopramide in the treatment of functional dyspepsia.
Key wordsDyspepsia/DT    Pharmaceutical Preparations
收稿日期: 2017-04-18     
PACS:  R573  
通讯作者: **,E-mail:monkey-loves@163.com   
引用本文:   
魏铁军, 张恒, 郭艺静, 张永利, 姜萌, 白云磊. 左舒必利、多潘立酮和胃复安治疗功能性消化不良的安全性及疗效比较[J]. 医学临床研究, 2018, 35(12): 2332-2334.
WEI Tie-jun, ZHANG Heng, GUO Yi-jing, et al. Safety and Efficacy of Levosulpiride, Domperidone and Metoclopramide in the Treatment of Functional Dyspepsia. JOURNAL OF CLINICAL RESEARCH, 2018, 35(12): 2332-2334.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2018.12.014     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2018/V35/I12/2332
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn